AsiaNet 86395

BETHESDA, Maryland, Nov. 3, 2020 /PRNewswire=KYODO JBN/ --

RevImmune, a privately held biotech company based in Paris, France and

Bethesda, MD, developing CYT107 (recombinant human Interleukin-7) for

infectious diseases, sepsis and cancer, announced today that its "ILIAD-7"

international randomized controlled Phase 2 trial in patients critically ill

with COVID-19, is now enrolling patients at 5 sites in the U.S. The trial has

already been under way for some time in the U.K. and France and is about to

start in Brazil.  

Logo - https://mma.prnewswire.com/media/1196997/RevImmune_Logo.jpg

This ILIAD-7 trial has started enrolling patients at Barnes Jewish

Hospital-Missouri Baptist Medical Center and Washington University in St.

Louis, and 4 additional sites: the Cleveland Clinic, Stony Brook University

Hospital, the University of Florida Medical Center, and Rutgers New Brunswick

Medical Center. Additional sites are in process.

Dr. Kenneth Remy, physician-scientist at Washington University in St. Louis

explains, "data over the past few months from our laboratory and a growing body

of literature from others regarding COVID-19 has demonstrated that patients

have a sustained and severe loss of lymphocytes with a profound immune

suppression rather than exclusively a cytokine storm. Patients who succumb to

COVID-19 have the most severe loss of lymphocytes and have a high incidence of

developing secondary hospital-acquired infections."  

Dr. Vidula Vachharajani, Professor of Medicine, Cleveland Clinic Lerner College

of Medicine, stated that "IL-7 offers a potential new way to restore immunity

in COVID-19 patients and may reduce the incidence of secondary hospital

acquired infections."  

To date, CYT107 has been administered in clinical trials to over 500 patients

with diverse infectious diseases, sepsis and cancers, with an excellent safety

profile and encouraging results. The primary mechanism of action of CYT107

works to restore lymphocyte function and increase lymphocyte proliferation of

lymphocytes thereby aiding in the elimination of invading pathogens.

Early success with CYT107 in critically ill COVID-19 patients, published in the

Journal of American Medical Association (JAMA) Open Network in August, showed

that CYT 107 improved absolute lymphocyte counts in 12 compassionate use

patients with COVID-19.  

The CYT107 treatment being tested in the current phase 2 randomized controlled

trial is designed to improve survival in critically ill patients with hypoxemia

and severe lymphopenia (low lymphocyte counts). The study is currently

enrolling at 5 sites in the U.S., and is expected to continue through December.

SOURCE  RevImmune Inc

CONTACT: Dr. Michel Morre, Chief Scientific Officer, mmorre@revimmune.com